November 6, 2026

November 6, 2026

Study shows ocean sailing safe, feasible for adults with MS

People with multiple sclerosis (MS) may be able to enjoy ocean sailing as a way to stay active, a small study found, with participants showing no measurable decline in physical or cognitive function after a 10-day expedition. All participants completed the planned sailing activities, although two-thirds experienced some degree of seasickness. Testing after the expedition […]

November 5, 2026

Potential myelin-repair treatment for MS enters human testing

The first participant has been dosed in a Phase 1/2a clinical trial testing PRO-1562, an experimental oral treatment designed to repair myelin, the protective sheath around nerve fibers that is damaged in people with multiple sclerosis (MS). Developed by Progentos Therapeutics, PRO-1562 aims to help existing immature cells develop into myelin-producing cells, potentially restoring nerve […]

November 5, 2026

Study links exercise to better quality of life in multiple sclerosis

People with multiple sclerosis (MS) who report engaging in a lot of physical activity tend to have better quality of life and less walking-related disability, regardless of how long ago they were diagnosed, a new study found. The associations between physical activity and several quality-of-life measures were generally stronger among people diagnosed within the previous […]

November 4, 2026

Canadian families gain new therapy for children with relapsing MS

Children and teenagers in Canada with relapsing-remitting multiple sclerosis (RRMS) now have a second treatment option following Health Canada’s approval of the infusion therapy Ocrevus (ocrelizumab). The regulatory decision extends the use of Ocrevus to patients 10 and older. Previously authorized in Canada only for adults, Ocrevus joins daily oral Gilenya (fingolimod) as the only […]